secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2024-09-26T23:59:59+00:00
Accession:  0001213900-24-081948
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX provides pipeline update: BX004 Ph2b results in Q3 2025, BX211 Ph2 results in Q1 2025
--------------------------------------------------------------------------------

- BX004 for CF: Phase 2b topline results expected Q3 2025 (60 patients, 2:1 randomized).
- BX211 for DFO: Phase 2 topline results expected Q1 2025 (week 26) and Q1 2026 (week 52).
- Cash and cash equivalents $32.7M as of June 30, 2024.
- Presentation highlights: 14.3% of BX004 patients converted to PsA-negative sputum in Ph1b/2a Part 2.
- Peer phage therapy momentum cited: >100 compassionate use cases with 77% clinical improvement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390024081948/0001213900-24-081948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390024081948/ea0215609-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-081948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer